Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research

References

• Mulhall J P, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006; 3: 662–667
   PubMed Web of Science ®Google Scholar
• Kaufman J M, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26: 833–876
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Swerdloff R, Behre H M, Gooren L J, Kaufman J M, Legros J J, Lunenfeld B, Morley J E, Schulman C, Wang C, Weidner W, Wu F C. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2005; 8: 56–58
   PubMedGoogle Scholar
• Bhasin S, Cunningham G R, Hayes F J, Matsumoto A M, Snyder P J, Swerdloff R S, Montori V M. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995–2010
   PubMed Web of Science ®Google Scholar
• Parsons J K, Carter H B, Platz E A, Wright E J, Landis P, Metter E J. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005; 14: 2257–2260
   PubMed Web of Science ®Google Scholar
• Rhoden E L, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482–492
   PubMed Web of Science ®Google Scholar
• Stattin P, Lumme S, Tenkanen L, Alfthan H, Jellum E, Hallmans G, Thoresen S, Hakulinen T, Luostarinen T, Lehtinen M, Dillner J, Stenman U H, Hakama M. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004; 108: 418–424
   PubMed Web of Science ®Google Scholar
• Gooren L J, Saad F. Recent insights into androgen action on the anatomical and physiological substrate of penile erection. Asian J Androl 2006; 8: 3–9
   PubMed Web of Science ®Google Scholar
• Kelleher S, Conway A J, Handelsman D J. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004; 89: 3813–3817
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006
   PubMedGoogle Scholar
• Practice Committee of the American Society for Reproductive Medicine. Treatment of androgen deficiency in the aging male. Fertil Steril 2006; 86(5 Suppl)S236–240
   PubMedGoogle Scholar
• Black A M, Day A G, Morales A. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial?. BJU Int 2004; 94: 1066–1070
   PubMed Web of Science ®Google Scholar
• Travison T G, Morley J E, Araujo A B, O'Donnell A B, McKinlay J B. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab 2006; 91: 2509–2513
   PubMed Web of Science ®Google Scholar
• Yassin A A, Saad F. Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido®). World J Urol 2006; 24: 639–644
   PubMed Web of Science ®Google Scholar
• Yassin A A, Saad F. Improvement of sexual functions in men with late onset hypogonadism treated with testosterone only. J Sex Med 2006; 4: 497–502
   Google Scholar
• Rochira V, Balestrieri A, Madeo B, Granata A R, Carani C. Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. J Androl 2006; 27: 165–175
   PubMed Web of Science ®Google Scholar
• Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, Vardi Y. EAU Guidelines on erectile dysfunction: an update. Eur Urol 2006; 49: 806–815
   PubMed Web of Science ®Google Scholar
• Morales A, Buvat J, Gooren L J, Guay A T, Kaufman J M, Tan H M, Torres L O. Endocrine aspects of sexual dysfunction in men. J Sex Med 2004; 1: 69–81
   PubMed Web of Science ®Google Scholar
• Laaksonen D E, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen T P, Valkonen V P, Salonen R, Salonen J T. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036–1041
   PubMed Web of Science ®Google Scholar
• Kupelian V, Page S T, Araujo A B, Travison T G, Bremner W J, McKinlay J B. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91: 843–850
   PubMed Web of Science ®Google Scholar
• Kapoor D, Malkin C J, Channer K S, Jones T H. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005; 63: 239–250
   PubMed Web of Science ®Google Scholar
• Jackson G. The metabolic syndrome and erectile dysfunction: multiple vascular risk factors and hypogonadism. Eur Urol 2006; 50: 426–427
   PubMed Web of Science ®Google Scholar
• Kupelian V, Shabsigh R, Araujo A B, O'Donnell A B, McKinlay J B. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol 2006; 176: 222–226
   PubMed Web of Science ®Google Scholar